Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Amortizatization of Intangibles: 2023-2025

Historic Amortizatization of Intangibles for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $352,000.

  • Compass Therapeutics' Amortizatization of Intangibles rose 9.32% to $352,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 15.18%. This contributed to the annual value of $1.2 million for FY2024, which is 2.27% down from last year.
  • As of Q3 2025, Compass Therapeutics' Amortizatization of Intangibles stood at $352,000, which was up 31.84% from $267,000 recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Amortizatization of Intangibles ranged from a high of $352,000 in Q3 2025 and a low of $219,000 during Q4 2024.
  • Over the past 3 years, Compass Therapeutics' median Amortizatization of Intangibles value was $302,000 (recorded in 2023), while the average stood at $290,727.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first fell by 28.66% in 2024, then grew by 9.32% in 2025.
  • Over the past 3 years, Compass Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $307,000 in 2023, then declined by 28.66% to $219,000 in 2024, then rose by 9.32% to $352,000 in 2025.
  • Its Amortizatization of Intangibles stands at $352,000 for Q3 2025, versus $267,000 for Q2 2025 and $224,000 for Q1 2025.